The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
Clarke CE, Davies P. Systemic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease.// J. Neurol. Neurosurg. Psychiatry,2000.-V.69.-P.590-594.
Clarke CE. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence.// Mov. Disord., 1995.-V.10(No. 3).-P.250-256.
Clarkson ED, Freed CR: Development of fetal neuronal transplantation as a treatment for Parkinson's disease. Life Sci 65:2427, 1999
Crosby N J, K H O Deane, C E Clarke. Amantadine for dyskinesia in Parkinson's disease (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software
Deane K H O, Jones D, Playford E D, Ben-Shlomo Y, Clarke C E.. Physiotherapy versus placebo or no intervention in Parkinson's disease (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
Dubois B., Pillon B. Cognitive and behavioral aspects of movement disorders // In: J.Jankovic, E.Tolosa (eds). Parkinson's disease and movement disorders. 3nd ed. – Baltimore. Williams&Wilkins, 1998. -P.837-858.
Fahn S: Medical treatment of Parkinson's disease. J Neurol 245:15, 1998
Fernandez HH, Lapane KL. Does selegiline increase mortality among Parkinson patients in long-term care? Ann Neurol 2000; 48: 433. Abstract.
FitzGerald P.M., Jankovic J. Lower body parkinsonism: evidence for vascular etiology.// Mov.Disord., 1989. – V.4. – P. 249-260.
Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease.// Mov. Disord., 2000.-V.15.-P.201-211.
Giladi N. Freezing of gait. Clinical review. //Adv. Neurol., 2001.-V. 87.-P.191-197.
Gilman S., Low P.A., Quinn N. Consensus statement on the diagnosis of multiple system atrophy.//J. Auton. Nerv. Syst., 1998. –Vol.74. –Р.189-192.
Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and Clozapine: comparative effects on motor function in hallucinating Parkinson's disease patients// Neurology, 2000.-V.55.-P.1-6.
Golbe L.I. Epidemiology of movement disorders // In: J.Jankovic, E.Tolosa (eds). Parkinson's disease and movement disorders. 3nd ed. – Baltimore. Williams&Wilkins, 1998. -P.119-132.
Gottwald MD: Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson's disease: Review and current status. Exp Opin Invest Drugs 8:453, 1999
Guttman M, and the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 1997; 49: 1060-1065.
Hoehn M.M, Yahr H.D. Parkinsonism: Onset, Progression and mortality//Neurology, 1967. – V.V.17. – P.427-442
Hornykiewicz O. Brain neurotransmitter changes in Parkinson's disease. // Movement disorders, Neurology / Eds. C.D. Marsden, S. Fahn – London: Butterworth Scientific,1982. – V.2 – P. 41-58.
Hornykiewicz O. Dopamine and Parkinson's disease. A personal view of the past, the present, and the future. //Adv. Neurol., 2001a.-V.86.-P.1-11.
Hughes A.J. Diagnosis of idiopathic Parkinson's disease:a clinico-pathological study of 100 cases //J.Neurol. Neurosurg.Psychiatry, 1992. – V.55.- P.181-184.
Hughes A.J., Ben-Shlomo Y., Daniel S.E., et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathological study//Neurology, 1992.-V.42.-P.1142- 1146.
Jancovic J. International Classification of Diseases, Tenth Revision: Neurological Adaptation (ICD-10NA):Extrapyramidal and Movement Disorders // Movement Disorders, 1995, -V.10. -№5. -Р.535-540.
Jankovic J, Rajput AH, McDermott MP, et al. The evolution of diagnosis in early Parkinson's disease. Parkinson Study Group.// Arch. Neurol., 2000.-V.57.-P.369-372.
Jellinger K. The pathology of parkinsonism.// In: Movement disorders 2. Eds. C.D.Marsden, S.Fahn. Butterworth, 1987. – P.124-165.
Koller WC, Pahwa R, Lyons KE, et al: Surgical treatment of Parkinson's disease. J Neurol Sci 167:1, 1999
Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S, for the 053 Study Group. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. Neurology 1999; 53: 364-370.
Kumar R, Lozano AM, Kim YJ, et al: Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 51:850, 1998
Lieberman A, Ranhosky A, Korts D: Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study. Neurology 49:162, 1997
Lees A. J., Katzenschlager R., Head J. et al.. Ten-year follow-up of three different initial treatments in de-novo PD // Neurology, 2001. – V.57. -P. 154-161.
Litvan I., Bhatia K., Burn D.J. et al. SIC Task force appraisal of clinical diagnostic criteria for parkinsonian disorders.//Mov. Disord., 2003. — V. 18. – P. 467-486.
Marsden C.D. Parkinson's disease//J. Neurol. Neurosurg. Psychiatry, 1994.-V.57.-P.672-681.
Marsden C.D., Fahn S. Problems in Parkinson's disease and other akinetic-rigid syndromes // In: C.D.Marsden, S.Fahn (eds). Movement disorders 3. Cambrridge, Butterworth Heinemann, 1994. -P.117-123
Mathias C.J., Kimber J.R. Treatment of postural hypotension// J Neurol. Neurosurg. Psychiatry, 1998. -V.65. -P. 285-289.
McKeith I.G., Galasko D., Kosaka K. et al. Consensus guidlines for the clinical and pathologic diagnosis of dementia with Lewy bodies //Neurology, 1996. -V.47. -P.113-1124.
Miyasaki J.M., Martin W., Suchowersky O. et al. Practice parameter: Initiation of treatment for Parkinson disease: An evidence-based review. Neurology. 2002; 58:11-17.
Muller J, Wenning GK, Jellinger K, et al. Progression of Hoehn and Yahr stages in parkinsonian disorders: a clinicopathologic study. //Neurology, 2000.-V.55.-P.888-891.
Münchau A., Bhatia K.P. Pharmacological treatment of Parkinson's disease. Postgrad. Med. J. 2000; 76(October):602-610
Nutt JG, Carter JH, Van Houten L, et al. Short- and long-duration responses to levodopa during the first year of levodopa therapy. //Ann. Neurol., 1997.-V.42.-P.349-355.
Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. //Ann. Neurol., 1996.-V.39.-P.561-573.
Oertel W. Н., Quinn N. P. Parkinsonism // Neurological Disorders: Course and Treatment. — New York, 2002. — P. 715— 772.
Olanow C.W., Stocchi F. Why delaying levodopa is a good treatment strategy in early Parkinson’s Disease. Eur. J. Neurol., 2000;7 suppl. 1: S.3-8
Olanow C, Watts R, Koller W. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(suppl 5):S1–88.
Parkinson Study Group: Safety and efficacy of pramipexole in early Parkinson disease: A randomized dose-ranging study. JAMA 278:125, 1997
Ramaker C, van Hilten J. Bromocriptine versus levodopa in early Parkinson's disease. The Cochrane Library. Oxford: Update Software, 2000.
Rascol O, Brooks D, Korczyn A, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484–91.
Rascol O., Goetz C., Koller W. et al. Treatment interventions for Parkinson’s disease: an evidence based assessment.//Lancet, 2002. – V.359. –P.1589-1598.
Richard I.H. Depression in Parkinson’s disease.// Current Treatment Options in Neurology, 2000. – V.2. –P.263-273.
Riley D.E. Secondary Parkinsonism //In: J.Jankovic, E.Tolosa (eds). Parkinson's disease and movement disorders. 3nd ed. – Baltimore. Williams&Wilkins, 1998. -P.317-339.
Schumacher JM, Ellias SA, Palmer EP, et al: Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 54:1042, 2000
Schrag A, Ben-Shlomo Y, Brown R, et al. Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality.// Mov. Disord.,1998.-V.13.-P.885-894.
Schrag A., Ben-Solomo Y., Quinn N.P. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study//Lancet, 1999. -V.354. -P.1771-1775.
Stacy M., Jankovic J. Differential diagnosis of Parkinson’s disease and parkinsonism-plus syndromes // Neurol.Clin., 1992.-V.10. -P.341-359.
Starkstein S.E., Merello M. Psychiatric and cognitive disorders in Parkinson’s disease. Cambridge Universitu Press, 2002. -229 P.
Waters C.H. Diagnosis and management of Parkinson’s disease. 1999 –240P.
Wenning G.K., Ben-Solomo Y., Hughes A. et al. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson’s disease?// J. Neurol. Neurosurg. Psychiatry, 2000. -V.68. -P. 434-440.
Zesiewicz T., Baker M.J., Wahba M. et al, Autonomic nervous system dysfunction in Parkinson’s disease.//Current Treatment Options in Neurology, 2003. – V.5. – P.149-160.
|
